Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Alpha Tau typically reports earnings before market open, meaning Day 0 reflects the first full trading session where investors react to results, and Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-10 | +$0.46 (+3.50%) | $0.63 (4.79%) | +$0.67 (+4.93%) | $0.99 (7.28%) |
| 2026-05-18 | -$0.33 (-3.19%) | $1.00 (9.65%) | +$0.65 (+6.48%) | $1.10 (10.97%) |
| 2026-03-09 | +$0.30 (+4.68%) | $0.68 (10.61%) | +$0.13 (+1.94%) | $0.74 (11.03%) |
| 2025-11-20 | -$0.21 (-5.71%) | $0.38 (10.33%) | +$0.35 (+10.09%) | $0.40 (11.53%) |
| 2025-08-11 | +$0.17 (+5.01%) | $0.18 (5.31%) | -$0.31 (-8.71%) | $0.45 (12.77%) |
| 2025-05-19 | +$0.31 (+11.11%) | $0.27 (9.86%) | +$0.16 (+5.16%) | $0.34 (10.97%) |
| 2025-03-12 | +$0.06 (+2.31%) | $0.12 (4.52%) | -$0.04 (-1.50%) | $0.09 (3.38%) |
| 2024-11-19 | +$0.00 (+0.00%) | $0.06 (2.60%) | -$0.00 (-0.22%) | $0.05 (2.17%) |
| Avg Abs Move | 4.44% | 7.21% | 4.88% | 8.76% |
Alpha Tau has shown moderate post-earnings volatility, with an average absolute Day 0 move of 4.44% and Day +1 move of 4.88%. The stock's reaction has been relatively directional, with five of the past eight earnings dates showing positive Day +1 moves. The largest single-day move came in May 2025, when the stock jumped 11.11% on Day 0, while the most significant Day +1 move was a 10.09% gain in November 2025. Intraday ranges have been wider, averaging 7.21% on Day 0 and 8.76% on Day +1, suggesting the stock experiences meaningful intraday swings before settling. Recent earnings have seen more muted reactions—the August 2026 report produced only a 3.50% Day 0 move—but the May 2026 report (which coincided with the first REGAIN glioblastoma data) drove a 6.48% Day +1 gain with a 10.97% intraday range. Given the company's clinical-stage profile, price action appears more sensitive to trial updates and strategic announcements than to the actual earnings figures.
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 2) |
| Expected Move | $0.89 (7.38%) |
| Expected Range | $11.21 to $12.99 |
| Implied Volatility | 123.66% |
The options market is pricing a 7.38% expected move by the November 20 expiration, which is roughly in line with the stock's historical Day +1 average move of 4.88% but below the average Day +1 intraday range of 8.76%. This suggests options traders are anticipating typical earnings volatility rather than an outsized reaction, despite the recent REGAIN trial data release just days before the report. The expected move implies a trading range between $11.21 and $12.99, which would be consistent with recent post-earnings behavior unless the company delivers unexpected clinical updates or materially revised guidance.
Analysts have turned decisively bullish on Alpha Tau, with a Strong Buy consensus rating and an average price target of $21.50—representing 79% upside from the current $12.01 price. The current breakdown shows 4 Strong Buys, 0 Moderate Buys, 1 Hold, 0 Moderate Sells, and 0 Strong Sells, with an average recommendation score of 4.60 out of 5.0.
Sentiment has improved over the past month, with one analyst upgrading from Strong Sell to Strong Buy, reflecting growing confidence following the November REGAIN trial data. One month ago, the consensus was less enthusiastic at 3.80, with 3 Strong Buys, 1 Hold, and 1 Strong Sell. The shift underscores how the recent glioblastoma results—showing complete responses in five of six evaluable patients—have fundamentally changed the narrative around Alpha DaRT's clinical potential.
Price targets range from a low of $16.00 to a high of $30.00, with the mean target of $21.50 implying substantial upside. The bullish case centers on Alpha DaRT's "multiple shots on goal" across different tumor types, the potential for a first-half 2027 FDA approval in recurrent squamous cell carcinoma, and the transformational REGAIN data in one of oncology's most difficult indications. The lone Hold rating appears to reflect valuation concerns after the stock's recent rally rather than skepticism about the underlying technology—one analyst noted that "the next leg higher will require real revenue realization," which remains 2-3 years away.
Alpha Tau's technical setup heading into earnings is deteriorating, with the Barchart Technical Opinion flashing a Sell signal at just 8%—a sharp reversal from the Buy signal at 40% seen both last week and last month. This dramatic shift reflects recent weakness as the stock has pulled back from its post-REGAIN data highs.
Timeframe Analysis:
Trend Characteristics: The signal strength is at a Minimum level and the direction is Weakening, indicating the technical environment is fragile heading into the earnings release. This suggests limited momentum support if results disappoint.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $12.56 | 50-Day MA | $13.90 |
| 10-Day MA | $13.17 | 100-Day MA | $13.67 |
| 20-Day MA | $13.21 | 200-Day MA | $10.99 |
The stock is trading at $12.01, below all short- and intermediate-term moving averages—below the 5-day ($12.56), 10-day ($13.17), 20-day ($13.21), 50-day ($13.90), and 100-day ($13.67)—but remains above the 200-day moving average ($10.99). This configuration suggests the stock is in a near-term downtrend after peaking in early November following the REGAIN data release, but the longer-term uptrend from earlier in 2026 remains intact. The cluster of resistance between $12.56 and $13.90 will be critical to watch—a strong earnings reaction could quickly reclaim these levels, while further disappointment could test support at the 200-day. With technical momentum weakening and the stock below key short-term averages, the setup is cautionary for bulls unless the company delivers material positive surprises or clinical updates that reignite the recent rally.